131 related articles for article (PubMed ID: 19008105)
1. No more brain tangles with DeltaNp73.
Mattson MP; Ashery U
Trends Biochem Sci; 2009 Jan; 34(1):6-8. PubMed ID: 19008105
[TBL] [Abstract][Full Text] [Related]
2. p73 regulates neurodegeneration and phospho-tau accumulation during aging and Alzheimer's disease.
Wetzel MK; Naska S; Laliberté CL; Rymar VV; Fujitani M; Biernaskie JA; Cole CJ; Lerch JP; Spring S; Wang SH; Frankland PW; Henkelman RM; Josselyn SA; Sadikot AF; Miller FD; Kaplan DR
Neuron; 2008 Sep; 59(5):708-21. PubMed ID: 18786355
[TBL] [Abstract][Full Text] [Related]
3. Role of p73 in Alzheimer disease: lack of association in mouse models or in human cohorts.
Vardarajan B; Vergote D; Tissir F; Logue M; Yang J; Daude N; Ando K; Rogaeva E; Lee J; Cheng R; Brion JP; Ghani M; Shi B; Baldwin CT; Kar S; Mayeux R; Fraser P; Goffinet AM; George-Hyslop PS; Farrer LA; Westaway D
Mol Neurodegener; 2013 Feb; 8():10. PubMed ID: 23414597
[TBL] [Abstract][Full Text] [Related]
4. DeltaNp73: misunderstood protein?
Irwin MS
Cancer Biol Ther; 2006 Jul; 5(7):804-7. PubMed ID: 16921261
[No Abstract] [Full Text] [Related]
5. deltaNp73 facilitates cell immortalization and cooperates with oncogenic Ras in cellular transformation in vivo.
Petrenko O; Zaika A; Moll UM
Mol Cell Biol; 2003 Aug; 23(16):5540-55. PubMed ID: 12897129
[TBL] [Abstract][Full Text] [Related]
6. Possible oncogenic potential of DeltaNp73: a newly identified isoform of human p73.
Ishimoto O; Kawahara C; Enjo K; Obinata M; Nukiwa T; Ikawa S
Cancer Res; 2002 Feb; 62(3):636-41. PubMed ID: 11830511
[TBL] [Abstract][Full Text] [Related]
7. p73 haploinsufficiency causes tau hyperphosphorylation and tau kinase dysregulation in mouse models of aging and Alzheimer's disease.
Cancino GI; Miller FD; Kaplan DR
Neurobiol Aging; 2013 Feb; 34(2):387-99. PubMed ID: 22592019
[TBL] [Abstract][Full Text] [Related]
8. Proinflammatory cytokines and bile acids upregulate ΔNp73 protein, an inhibitor of p53 and p73 tumor suppressors.
Zaika E; Bhardwaj V; Wei J; Washington MK; Souza R; El-Rifai W; Zaika A
PLoS One; 2013; 8(5):e64306. PubMed ID: 23717592
[TBL] [Abstract][Full Text] [Related]
9. DeltaNp73 transcription factors modulate cell survival and tumor development.
Ravni A; Tissir F; Goffinet AM
Cell Cycle; 2010 Apr; 9(8):1523-7. PubMed ID: 20372082
[TBL] [Abstract][Full Text] [Related]
10. Complex regulation of p73 isoforms after alteration of amyloid precursor polypeptide (APP) function and DNA damage in neurons.
Benosman S; Meng X; Von Grabowiecki Y; Palamiuc L; Hritcu L; Gross I; Mellitzer G; Taya Y; Loeffler JP; Gaiddon C
J Biol Chem; 2011 Dec; 286(50):43013-25. PubMed ID: 22002055
[TBL] [Abstract][Full Text] [Related]
11. The jury is in: p73 is a tumor suppressor after all.
Rosenbluth JM; Pietenpol JA
Genes Dev; 2008 Oct; 22(19):2591-5. PubMed ID: 18832062
[TBL] [Abstract][Full Text] [Related]
12. Isoform-specific p73 knockout mice reveal a novel role for delta Np73 in the DNA damage response pathway.
Wilhelm MT; Rufini A; Wetzel MK; Tsuchihara K; Inoue S; Tomasini R; Itie-Youten A; Wakeham A; Arsenian-Henriksson M; Melino G; Kaplan DR; Miller FD; Mak TW
Genes Dev; 2010 Mar; 24(6):549-60. PubMed ID: 20194434
[TBL] [Abstract][Full Text] [Related]
13. Evidence that DeltaNp73 promotes neuronal survival by p53-dependent and p53-independent mechanisms.
Lee AF; Ho DK; Zanassi P; Walsh GS; Kaplan DR; Miller FD
J Neurosci; 2004 Oct; 24(41):9174-84. PubMed ID: 15483136
[TBL] [Abstract][Full Text] [Related]
14. Transdominant DeltaTAp73 isoforms are frequently up-regulated in ovarian cancer. Evidence for their role as epigenetic p53 inhibitors in vivo.
Concin N; Becker K; Slade N; Erster S; Mueller-Holzner E; Ulmer H; Daxenbichler G; Zeimet A; Zeillinger R; Marth C; Moll UM
Cancer Res; 2004 Apr; 64(7):2449-60. PubMed ID: 15059898
[TBL] [Abstract][Full Text] [Related]
15. Spatiotemporal switch from DeltaNp73 to TAp73 isoforms during nephrogenesis: impact on differentiation gene expression.
Saifudeen Z; Diavolitsis V; Stefkova J; Dipp S; Fan H; El-Dahr SS
J Biol Chem; 2005 Jun; 280(24):23094-102. PubMed ID: 15805112
[TBL] [Abstract][Full Text] [Related]
16. DeltaNp73, a dominant-negative inhibitor of wild-type p53 and TAp73, is up-regulated in human tumors.
Zaika AI; Slade N; Erster SH; Sansome C; Joseph TW; Pearl M; Chalas E; Moll UM
J Exp Med; 2002 Sep; 196(6):765-80. PubMed ID: 12235210
[TBL] [Abstract][Full Text] [Related]
17. Involvement of N-terminally truncated variants of p73, deltaTAp73, in head and neck squamous cell cancer: a comparison with p53 mutations.
Faridoni-Laurens L; Tourpin S; Alsafadi S; Barrois M; Temam S; Janot F; Koscielny S; Bosq J; Bénard J; Ahomadegbe JC
Cell Cycle; 2008 Jun; 7(11):1587-96. PubMed ID: 18469517
[TBL] [Abstract][Full Text] [Related]
18. Characterization of ΔNp73 expression and regulation in gastric and esophageal tumors.
Vilgelm AE; Hong SM; Washington MK; Wei J; Chen H; El-Rifai W; Zaika A
Oncogene; 2010 Oct; 29(43):5861-8. PubMed ID: 20676143
[TBL] [Abstract][Full Text] [Related]
19. Family friction as ΔNp73 antagonises p73 and p53.
Bailey SG; Cragg MS; Townsend PA
Int J Biochem Cell Biol; 2011 Apr; 43(4):482-6. PubMed ID: 21216303
[TBL] [Abstract][Full Text] [Related]
20. Questioning the oncogenic role of DeltaNp73alpha in different cell lines expressing p53 or not.
Marrazzo E; Marchini S; Previdi S; Broggini M
Cancer Biol Ther; 2006 Jul; 5(7):794-803. PubMed ID: 16721041
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
